9 terminated, 8 completed, 2 withdrawn, 1 active not recruiting. 12 Phase 2, 10 Phase 1, 2 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow PEGPH20: new trials by email Literature Review of PEGPH20 trials Research Report on PEGPH20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer Pegylated Recombinant Human Hyaluronidase PH20, Pembrolizumab - Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-02-01 | 2020-03-13 | |
| MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma Pegvorhyaluronidase alfa, Abraxane, Gemcitabine - Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | Abramson Cancer Center at Penn Medicine | 2020-01-01 | 2020-01-31 | |
| Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma Atezolizumab, PEGPH20 - Pancreatic Ductal Adenocarcinoma | Phase 2 | Terminated | Gulam Manji | 1 | 2019-11-01 | 2020-12-23 |
| Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC PEGPH20, Pembrolizumab - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Phase 2 | Unknown | Pancreatic Cancer Research Team | 35 | 2019-05-01 | 2019-05-07 |
| A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer PEGylated Recombinant Human Hyaluronidase (PEGPH20), Avelumab - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer | Early Phase 1 | Terminated | PH Research, S.L. | 7 | 2018-01-10 | 2019-08-22 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin - Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 219 | 2017-10-13 | 2026-08-03 |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma PEGPH20, CIS, GEM - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic | Phase 1 | Terminated | Halozyme Therapeutics | 85 | 2017-10-02 | 2020-02-07 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Nab-Paclitaxel, Gemcitabine, Oxaliplatin - Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 341 | 2017-07-05 | 2025-11-21 |
| PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation - Pancreatic Adenocarcinoma Non-resectable | Phase 2 | Terminated | Scripps Health | 4 | 2017-01-03 | 2019-04-11 |
| Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma Gemcitabine, Nab-paclitaxel, PEGPH20 - Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma | Not applicable | Active not recruiting | Memorial Sloan Kettering Cancer Center | 110 | 2016-10-01 | 2026-11-04 |
| Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase - Metastatic Breast Cancer | Phase 1 / Phase 2 | Terminated | Eisai Inc. | 25 | 2016-07-13 | 2020-07-13 |
| A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Placebo, nab-Paclitaxel - Pancreatic Ductal Carcinoma | Phase 3 | Terminated | Halozyme Therapeutics | 492 | 2016-03-14 | 2020-07-14 |
| A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors PEGPH20, Pembrolizumab - NSCLC, Gastric Cancer | Phase 1 | Completed | Halozyme Therapeutics | 56 | 2015-10-22 | 2020-02-07 |
| PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma PEGPH20, Gemcitabine, Nab-paclitaxel - Adenocarcinoma | Phase 2 | Terminated | Andrew Ko | 3 | 2015-07-14 | 2020-01-02 |
| A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC PEGylated recombinant human hyaluronidase PH20, Docetaxel - Non-small Cell Lung Cancer | Phase 1 | Terminated | Halozyme Therapeutics | 16 | 2015-02-10 | 2019-02-08 |
| Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection PEGPH20, Cetuximab, DW & DCE-MRI - Pancreatic Cancer | Not applicable | Completed | Memorial Sloan Kettering Cancer Center | 2 | 2014-09-12 | 2017-09-27 |
| S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer PEGPH20, Oxaliplatin, Leucovorin - Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | SWOG Cancer Research Network | 126 | 2014-01-23 | 2024-02-09 |
| PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer PEGPH20, Nab-paclitaxel, Gemcitabine - Metastatic Pancreatic Cancer | Phase 2 | Completed | Halozyme Therapeutics | 279 | 2013-05-14 | 2020-07-20 |
| Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer Gemcitabine, PEGPH20, Placebo - Stage IV Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Halozyme Therapeutics | 28 | 2011-09-01 | 2018-11-30 |
| Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors PEGPH20 - Solid Tumor | Phase 1 | Completed | Halozyme Therapeutics | 27 | 2010-07-01 | 2014-01-29 |
Showing 20 of 21. Sign in to see all of them.
Pancreatic Neoplasms (8) · Neoplasm Metastasis (3) · Adenocarcinoma (2) · Carcinoma, Pancreatic Ductal (2) · Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Esophageal Neoplasms (1) · Recurrence (1) · Stomach Neoplasms (1) · Thromboembolism (1)
Halozyme Therapeutics (8) · Hoffmann-La Roche (2) · Memorial Sloan Kettering Cancer Center (2) · Abramson Cancer Center at Penn Medicine (1) · Andrew Ko (1) · Eisai Inc. (1) · Gulam Manji (1) · M.D. Anderson Cancer Center (1) · PH Research, S.L. (1) · Pancreatic Cancer Research Team (1) · SWOG Cancer Research Network (1) · Scripps Health (1)
United States (20) · South Korea (4) · Spain (4) · Australia (2) · Germany (2) · Israel (2) · Taiwan (2) · United Kingdom (2) · Belgium (1) · Brazil (1) · Canada (1) · Croatia (1) · Czechia (1) · Denmark (1) · Estonia (1)
Joy Zhu, M.D. (2) · Andrew Ko, MD (1) · Darren S Sigal, MD (1) · David R Fogelman (1) · Gabriella Chiorean, MD (1) · Gulam Manji, MD, PhD (1) · Joy H Zhu, MD, PhD (1) · Kenneth Yu, MD MSc (1) · Kenneth Yu, MD, MSc (1) · Ramesh K Ramanathan, M.D. (1) · Thomas Karasic, MD (1)
PMID 36940261, PMID 29232172, PMID 30817250, PMID 33478521, PMID 33982408, PMID 39707623, PMID 41449151
2015 (2), 2016 (2), P30CA016672 (1), U10CA180888 (1)